PDF(Sci-hub)
Abstract：
To determine the effects of the intraocular injection of antivascular endothelial growth factor (anti-VEGF) drugs on the refractive status of infants with retinopathy of prematurity (ROP).
Systematic review and meta-analysis of the refractive status of infants with ROP who receive anti-VEGF drugs.
The PubMed, Web of Science and Embase databases and the ClinicalTrials.gov website were searched up to June 2020.
We included randomised controlled trials (RCTs) and observational studies that compared refractive errors between anti-VEGF drug and laser therapies.
Data extraction and risk-of-bias assessments were conducted by two independent reviewers. We used a random-effect model to pool outcomes. The outcome measures were the spherical equivalents, axial length (AL), anterior chamber depth (ACD) and lens thickness (LT).
Thirteen studies involving 1850 eyes were assessed: 914 in the anti-VEGF drug group, and 936 in the control (laser) group. Children who received anti-VEGF drug treatment had less myopia than those who received laser therapy (mean difference=1.80 D, 95% CI 0.97 to 2.63, p＜0.0001, I2=78%). The AL, ACD and LT did not reach statistical significance difference between the two groups. The current evidence indicates that the refractive safety in children with ROP is better for anti-VEGF drug treatment than for laser therapy.
This meta-analysis indicates that anti-VEGF drug therapy results in less myopia compared with laser therapy. However, there are relatively few published articles on refractive errors in ROP, and so high-quality and powerful RCTs are needed in the future.
CRD42020160673.
Systematic review and meta-analysis of the refractive status of infants with ROP who receive anti-VEGF drugs.
The PubMed, Web of Science and Embase databases and the ClinicalTrials.gov website were searched up to June 2020.
We included randomised controlled trials (RCTs) and observational studies that compared refractive errors between anti-VEGF drug and laser therapies.
Data extraction and risk-of-bias assessments were conducted by two independent reviewers. We used a random-effect model to pool outcomes. The outcome measures were the spherical equivalents, axial length (AL), anterior chamber depth (ACD) and lens thickness (LT).
Thirteen studies involving 1850 eyes were assessed: 914 in the anti-VEGF drug group, and 936 in the control (laser) group. Children who received anti-VEGF drug treatment had less myopia than those who received laser therapy (mean difference=1.80 D, 95% CI 0.97 to 2.63, p＜0.0001, I2=78%). The AL, ACD and LT did not reach statistical significance difference between the two groups. The current evidence indicates that the refractive safety in children with ROP is better for anti-VEGF drug treatment than for laser therapy.
This meta-analysis indicates that anti-VEGF drug therapy results in less myopia compared with laser therapy. However, there are relatively few published articles on refractive errors in ROP, and so high-quality and powerful RCTs are needed in the future.
CRD42020160673.
摘要：
探讨眼内注射抗血管内皮生长因子(抗VEGF)药物对早产儿视网膜病变(ROP)患儿屈光状态的影响。
接受抗VEGF药物的ROP婴儿屈光状态的系统评价和荟萃分析。
PubMed,截至2020年6月，搜索了WebofScience和Embase数据库以及ClinicalTrials.gov网站。
我们纳入了随机对照试验（RCT）和观察性研究，比较了抗VEGF药物和激光治疗的屈光不正。
数据提取和偏倚风险评估由两名独立审阅者进行。我们使用随机效应模型来汇集结果。结果测量是球形当量，轴向长度（AL），前房深度（ACD）和晶状体厚度（LT）。
对涉及1850只眼的13项研究进行了评估：抗VEGF药物组914项，和936在对照(激光)组中。接受抗VEGF药物治疗的儿童近视程度低于接受激光治疗的儿童（平均差异=1.80D，95%CI0.97~2.63，p＜0.0001，I2=78%）。AL,ACD和LT两组间差异无统计学意义。目前的证据表明，抗VEGF药物治疗ROP患儿的屈光安全性优于激光治疗。
该荟萃分析表明，与激光治疗相比，抗VEGF药物治疗导致近视减少。然而,发表的关于ROP屈光不正的文章相对较少，因此，未来需要高质量和强大的RCT。
CRD42020160673。
接受抗VEGF药物的ROP婴儿屈光状态的系统评价和荟萃分析。
PubMed,截至2020年6月，搜索了WebofScience和Embase数据库以及ClinicalTrials.gov网站。
我们纳入了随机对照试验（RCT）和观察性研究，比较了抗VEGF药物和激光治疗的屈光不正。
数据提取和偏倚风险评估由两名独立审阅者进行。我们使用随机效应模型来汇集结果。结果测量是球形当量，轴向长度（AL），前房深度（ACD）和晶状体厚度（LT）。
对涉及1850只眼的13项研究进行了评估：抗VEGF药物组914项，和936在对照(激光)组中。接受抗VEGF药物治疗的儿童近视程度低于接受激光治疗的儿童（平均差异=1.80D，95%CI0.97~2.63，p＜0.0001，I2=78%）。AL,ACD和LT两组间差异无统计学意义。目前的证据表明，抗VEGF药物治疗ROP患儿的屈光安全性优于激光治疗。
该荟萃分析表明，与激光治疗相比，抗VEGF药物治疗导致近视减少。然而,发表的关于ROP屈光不正的文章相对较少，因此，未来需要高质量和强大的RCT。
CRD42020160673。
